216 related articles for article (PubMed ID: 23247012)
21. Solifenacin in women with de novo overactive bladder after tension-free obturator vaginal tape--is it effective?
Serati M; Braga A; Sorice P; Siesto G; Salvatore S; Ghezzi F
J Urol; 2014 May; 191(5):1322-6. PubMed ID: 24148761
[TBL] [Abstract][Full Text] [Related]
22. Solifenacin for therapy resistant overactive bladder.
Hoebeke P; De Pooter J; De Caestecker K; Raes A; Dehoorne J; Van Laecke E; Vande Walle J
J Urol; 2009 Oct; 182(4 Suppl):2040-4. PubMed ID: 19695608
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies.
Franco I; Hoebeke P; Baka-Ostrowska M; Bolong D; Davies LN; Dahler E; Snijder R; Stroosma O; Verheggen F; Newgreen D; Bosman B; Vande Walle J
J Pediatr Urol; 2020 Apr; 16(2):180.e1-180.e8. PubMed ID: 32007426
[TBL] [Abstract][Full Text] [Related]
24. Solifenacin.
Kreder KJ
Urol Clin North Am; 2006 Nov; 33(4):483-90, ix. PubMed ID: 17011384
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
26. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.
Madersbacher H; Mürtz G; Alloussi S; Domurath B; Henne T; Körner I; Niedeggen A; Nounla J; Pannek J; Schulte-Baukloh H; Schultz-Lampel D; Bock P; Strugala G
BJU Int; 2009 Mar; 103(6):776-81. PubMed ID: 19007380
[TBL] [Abstract][Full Text] [Related]
27. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.
Grosse J; Kramer G; Jakse G
BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462
[TBL] [Abstract][Full Text] [Related]
28. The Stockholm Spinal Cord Uro Study: 3. Urodynamic characteristics in a regional prevalence group of persons with spinal cord injury and indications for improved follow-up.
Farrelly E; Lindbo L; Seiger Å
Scand J Urol; 2021 Oct; 55(5):412-418. PubMed ID: 34279177
[TBL] [Abstract][Full Text] [Related]
29. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Giannantoni A; Mearini E; Del Zingaro M; Porena M
Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
31. Urodynamic Differences between Complete and Incomplete Spinal Cord Injuries with Neurogenic Detrusor Overactivity.
García Fadrique G; Gallego D; Ordaz D; Climent L
Urol Int; 2020; 104(3-4):273-276. PubMed ID: 31461727
[TBL] [Abstract][Full Text] [Related]
32. Solifenacin: scientific evidence in the treatment of overactive bladder.
Santos JC; Telo ER
Arch Esp Urol; 2010 Apr; 63(3):197-213. PubMed ID: 20431184
[TBL] [Abstract][Full Text] [Related]
33. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.
Toglia MR; Serels SR; Laramée C; Karram MM; Nandy IM; Andoh M; Seifeldin R; Forero-Schwanhaeuser S
Postgrad Med; 2009 Sep; 121(5):151-8. PubMed ID: 19820284
[TBL] [Abstract][Full Text] [Related]
34. Neurogenic detrusor overactivity: comparison between complete and incomplete spinal cord injury patients.
Moslavac S; Dzidic I; Kejla Z
Neurourol Urodyn; 2008; 27(6):504-6. PubMed ID: 18508334
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of propiverine hydrochloride extended-release compared with immediate-release in patients with neurogenic detrusor overactivity.
Stöhrer M; Mürtz G; Kramer G; Warnack W; Primus G; Jinga V; Manu-Marin A; Calomfirescu N; Strugala G
Spinal Cord; 2013 May; 51(5):419-23. PubMed ID: 23338657
[TBL] [Abstract][Full Text] [Related]
36. Protocol for a phase II, open-label exploratory study investigating the efficacy of fesoterodine for treatment of adult patients with spinal cord injury suffering from neurogenic detrusor overactivity for amelioration of autonomic dysreflexia.
Walter M; Ramirez AL; Lee AH; Rapoport D; Kavanagh A; Krassioukov AV
BMJ Open; 2018 Nov; 8(11):e024084. PubMed ID: 30467135
[TBL] [Abstract][Full Text] [Related]
37. Solifenacin at 3 years: a review of efficacy and safety.
Pelman RS; Capo JP; Forero-Schwanhaeuser S
Postgrad Med; 2008 Jul; 120(2):85-91. PubMed ID: 18654073
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity.
Chen SF; Kuo HC
J Formos Med Assoc; 2015 Jul; 114(7):583-9. PubMed ID: 24262922
[TBL] [Abstract][Full Text] [Related]
39. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
[TBL] [Abstract][Full Text] [Related]
40. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
